Citadel Advisors
IDYA icon

Citadel Advisors’s IDEAYA Biosciences IDYA Stock Holding History

Citadel Advisors’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.44M Sell
38,600
-39,900
-51% -$1.22M ﹤0.01% 7319
2026
Q1 		$2.62M Buy
78,500
+59,600
+315% +$2M ﹤0.01% 5530
2025
Q4 		$653K Buy
+18,900
New +$603K ﹤0.01% 8365
2025
Q3 		– Sell
-21,000
Closed -$441K – 13379
2025
Q2 		$441K Sell
21,000
-9,500
-31% -$182K ﹤0.01% 8932
2025
Q1 		$500K Buy
30,500
+6,400
+27% +$136K ﹤0.01% 8478
2024
Q4 		$619K Buy
24,100
+17,400
+260% +$493K ﹤0.01% 8077
2024
Q3 		$212K Sell
6,700
-1,800
-21% -$68.3K ﹤0.01% 10021
2024
Q2 		$298K Buy
8,500
+6,000
+240% +$238K ﹤0.01% 9148
2024
Q1 		$110K Sell
2,500
-1,400
-36% -$60.2K ﹤0.01% 11226
2023
Q4 		$139K Sell
3,900
-5,600
-59% -$167K ﹤0.01% 10511
2023
Q3 		$256K Sell
9,500
-200
-2% -$5.07K ﹤0.01% 9452
2023
Q2 		$228K Buy
+9,700
New +$199K ﹤0.01% 9594
2023
Q1 		– Sell
-400
Closed -$7.27K – 15061
2022
Q4 		$7.27K Buy
+400
New +$6.73K ﹤0.01% 13836

Other funds holding IDYA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Citadel Advisors's IDYA Position: Q2 2026 in Review

Citadel Advisors reduced its IDEAYA Biosciences (IDYA) stake by 56% in Q2 2026, selling an estimated $11.6M and leaving 300,438 shares worth $11.2M. The position accounts for ﹤0.01% of the portfolio, ranked #3402.

Citadel Advisors first reported a position in IDYA in Q2 2020 and has held it in 20 quarters since. The position peaked at $62.8M in Q1 2024. 286 funds tracked by Wall St. Rank hold IDYA as of Q2 2026.

  • Citadel Advisors held 300,438 shares of IDEAYA Biosciences worth $11.2M as of Q2 2026.
  • Citadel Advisors sold 378,962 IDEAYA Biosciences shares in Q2 2026, an estimated $11.6M.
  • IDEAYA Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3402 holding.
  • Citadel Advisors first reported a position in IDEAYA Biosciences in Q2 2020 and has held it in 20 quarters since.
  • Citadel Advisors's IDEAYA Biosciences position peaked at $62.8M in Q1 2024.
  • 286 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.